Clozapine as a treatment for psychosis in Parkinson's disease: A review

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 8, Issue 1, 1996, Pages 1-9

  Musser, William S ^a   Akil, Mayada ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

CLINICAL FEATURE; CONFUSION; DELIRIUM; DELUSION; DROWSINESS; HEART PALPITATION; HUMAN; HYPERSALIVATION; LETHARGY; LEUKOPENIA; MOTOR DYSFUNCTION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SYMPTOM; SYNCOPE; VISUAL HALLUCINATION; WEIGHT GAIN;

EID: 0030050424     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.8.1.1     Document Type: Review

References (52)

1. Goodwin FK: Behavorial effects of L-dopa in man. Semin Psychiatry 1971; 3:477-492
2. Cummings JL: Depression and Parkinson's disease: a review. Am J Psychiatry. 1992; 149:443-454
3. Boyd JL, Cruickshank CA, Kenn CW, et al: Cognitive impairment and dementia in Parkinson's disease: a controlled study. Psychol Med 1991; 21:911-921
4. Duyckaerts C, Gaspar P, Coosta C, et al: Dementia in Parkinson's disease: morphometric data. Adv Neurol 1993; 60:447-455
5. Barbeau A: L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J 1969; 101:59-68
6. Greene P, Cote L, Fahn S: Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993; 60:703-706
7. Birkmayer W, Riederer P, Rausch WD: Neuropharmacological principles and problems of combined L-dopa treatment in Parkinson's disease. Adv Neurol 1979; 24:499-510
8. Stern Y, Mayeux R, Ilson J, et al: Pergolide therapy for Parkinson's disease: neurobehavorial changes. Neurology 1984; 34:201-204
9. Lieberman AN, Kupersmith M, Neophytides A, et al: Bromocriptine in Parkinson's disease: report on 106 patients treated for up to 5 years, in Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects, edited by Goldstein M, Calne DB, Lieberman AN, et al. New York, Raven, 1980, pp 245-253
10. Sacks OW, Kohl MS, Merseloff CR, et al: Effects of levodopa in parkinsonian patients with dementia. Neurology 1972; 22:516-519
11. McDowell FH: Changes in behavior and mentation, in L-dopa and Parkinsonism, edited by Barbeau A, McDowell FH, Philadelphia, FA Davis, 1970, pp 321-347
12. Celesia GG, Barr AN: Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970; 23:193-200
13. Hale MS, Bellizzi J: Low dose perphenazine and levodopa/carbidopa therapy in a patient with parkinsonism and a psychotic illness. J Nerv Ment Dis 1980; 168:312-314
14. Hurwitz TA, Calne DB, Waterman K: Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 1988; 15:32-34
15. Rich SS, Friedman JH: Treatment of psychosis in Parkinson's disease, in Medical Psychiatric Practice, edited by Stoudemire A, Fogel BS. Washington, DC, American Psychiatric Press, 1995, pp 151-182
16. Shaw KM, Lees AJ, Stern GM: The impact of treatment with levodopa on Parkinson's disease. Q J Med 1980; 195:283-293
17. Goetz CG, Tanner CM, Klawans HL: Drug holiday in the management of Parkinson's disease. Clin Neuropharmacol 1982; 5:351-364
18. Lipper S: Psychosis in a patient on bromocriptine and levodopa with carbidopa (letter). Lancet 1976; 1:571-572
19. Polvsen UJ, Noring U, Fog R, et al: Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71:176-185
20. Goldstein M, Deutch AY: Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J 1992; 6:2413-2421
21. Roberts HE, Dean RC, Stoudemire A: Clozapine treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1989; 1:190-192
22. Rosenthal SH, Fenton ML, Harnett DS: Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease (letter). Gen Hosp Psychiatry 1992; 14:285-286
23. Friedman JH, Lannon MC: Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989; 39:1219-1221
24. Gershanik D, Garcia S, Papa S, et al: Analysis of the mechanism of action of clozapine in Parkinson's disease (abstract). Mov Disord 1992; 7 (suppl 1):101
25. Bear D, Lawson W, Burns S, et al: Clozapine in idiopathic Parkinson's (abstract). Biol Psychiatry 1989; 25:160A-165A
26. Friedman JH, Lannon MC, Caley C: Clozapine for movement disorder patients: a retrospective analysis of 38 patients (abstract). Ann Neurol 1992; 32:277
27. Ostergaard K, Dupont E: Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson's disease (letter). Acta Neurol Scand 1988; 78:349-350
28. Factor SA, Brown D: Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992; 7:125-131
29. Kahn N, Freeman A, Juncos JL, et al: Clozapine is beneficial for psychosis in Parkinson's disease (letter). Neurology 1991; 41:1699-1700
30. Bernardi F, DelZompo M: Clozapine in idiopathic Parkinson's disease (letter). Neurology 1990; 40:1151-1152
31. Scholz E, Dichgans J: Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985; 235:60-64
32. Pfeiffer RF, Kang J, Graber B, et al: Clozapine for psychosis in Parkinson's disease. Mov Disord 1990; 5:239-242
33. Lew MF, Waters CH: Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 1993; 41:669-671
34. Factor SA, Brown D, Molho ES, et al: Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994; 44:544-546
35. Wolters EC, Hurwitz TA, Mak E, et al: Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40:832-834
36. Borison RL, Diamond BI, Sinha D, et al: Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 1988; 24:260-263
37. Perenyi A, Kuncz E, Bagdy G: Early relapse after sudden withdrawal or dose reduction of clozapine (letter). Psychopharmacology (Berlin) 1985; 86:244
38. Pakkenberg H, Pakkenberg B: Clozapine in the treatment of tremor. Acta Neurol Scand 1986; 73:295-297
39. Friedman JH, Lannon MC: Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990; 5:225-229
40. Fisher PA, Baas H, Hefner R: Treatment of parkinsonian tremor with clozapine (rapid communication). J Neural Transm [P-D Sect] 1990; 2:233-238
41. Bennett JP Jr, Landlow ER, Schuh LA: Suppression of dyskinesias in advanced Parkinson's disease, II: increasing daily clozapine doses suppress dyskinesias and improve parkinsonian symptoms. Neurology 1993; 43:1551-1555
42. Linazasoro G, Marti Masso JF, Suarez JA: Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Mov Disord 1993; 8:171-174
43. Cohen BM, Keck PE, Satlin A, et al: Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1991; 29:1215-1219
44. Alvir JMJ, Lieberman JA, Safferman AZ, et al: Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329:162-167
45. Meltzer HY, Cola PA: The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994; 55(suppl B):161-165
46. Chouinard G, Jones B, Remington G, et al: Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
47. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
48. Meco G, Alessandria A, Bonifati V, et al: Risperidone for hallucinations in levodopa-treated Parkinson's disease patients (letter). Lancet 1994; 2:1370-1371
49. Ford B, Lynch T, Greene P: Risperidone in Parkinson's disease (letter). Lancet 1994; 1:344:681
50. 2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology 1993; 110:265-272
51. Melamed E, Zoldan J, Friedberg G, et al: Is hallucinosis in Parkinson's disease due to central serotonergic hyperactivity? Mov Disord 1993; 8:406-407
52. Zoldan J, Friedberg G, Goldberg SH, et al: Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 1:562-563